Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.

Antimicrobial agents and chemotherapy - 1 Nov 2017

Lomovskaya Olga, Sun Dongxu, Rubio-Aparicio Debora, Nelson Kirk, Tsivkovski Ruslan, Griffith David C, Dudley Michael N

Abstract excerpt

Vaborbactam (formerly RPX7009) is a new beta-lactamase inhibitor based on a cyclic boronic acid pharmacophore. The spectrum of beta-lactamase inhibition by vaborbactam and the impact of bacterial efflux and permeability on its activity were determined using a panel of strains with beta-lactamases cloned from various classes and a panel of Klebsiella pneumoniae carbapenemase 3 (KPC-3)-producing isogenic strains...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta-Lactam Resistance
Share to beta-Lactamase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Boronic Acids

Share to Carbapenems

Share to Enterobacteriaceae

Share to Meropenem

Share to Porins

Share to Thienamycins

Source

Open in PubMed Open full text

Identifiers

PMID: 28848018
DOI: 10.1128/AAC.01443-17
PMCID: PMC5655098

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.PMID 28848018Read ↗

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.Semantic proximity Read ↗

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive EnterobacteriaceaeSemantic proximity Read ↗

Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant EnterobacteriaceaeSemantic proximity Read ↗

Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.Semantic proximity Read ↗

QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological CharacteristicsSemantic proximity Read ↗

In vitro-obtained meropenem-vaborbactam resistance mechanisms among clinical Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolatesSemantic proximity Read ↗

Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018Semantic proximity Read ↗

Comparison of meropenem-vaborbactam with ceftazidime-avibactam in the treatment of carbapenem-resistant Enterobacterales infectionsSemantic proximity Read ↗

A molecular analysis of meropenem-vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae.Semantic proximity Read ↗

Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteriaSemantic proximity Read ↗

Cefepime–taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa : GEARS global surveillance programme 2018–22Semantic proximity Read ↗

New Carbapenemase Inhibitors: Clearing the Way for the β-LactamsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.